This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-25. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Methods incorporating chromatography generally begin with cryodepleted plasma undergoing buffer exchange via either diafiltration or buffer exchange chromatography, to prepare the plasma for following ion exchange chromatography steps. After ion exchange there are generally further chromatographic purification steps and buffer exchange. For further information see chromatography in blood processing.
The chemical model will include values of the protonation constants of the ligand, which will have been determined in separate experiments, a value for log Kw and estimates of the unknown stability constants of the complexes formed. These estimates are necessary because the calculation uses a non-linear least-squares algorithm. The estimates are usually obtained by reference to a chemically similar system. The stability constant databases can be very useful in finding published stability constant values for related complexes. In some simple cases the calculations can be done in a spreadsheet. Otherwise, the calculations are performed with the aid of a general-purpose computer programs. The most frequently used programs are:
The properties of quantum dots can be also tuned by the synthetic scheme, high temperature solvent/ligand mixtures that influence the nanocrystal properties. High-quality QD contrast agents are obtained at elevated temperatures; however, because they have lower water solubility, their usage as cell markers is limited. Further functionalization with hydrophilic ligands is required. The advantages of QD are represented by their fast action; they are able to label a target tissue or cell in seconds. In vivo studies show that QD are able to selectively label cancer cells, and they accumulate at tumor sites. Tumor cells labeled with QD can be tracked with multiphoton microscopy as they invade lung tissue. In both studies, spectral imaging and autofluorescent subtraction allowed multicolour in vivo visualization of cells and tissues. A major drawback of QD is their relatively high toxicity. Functionalizations with different substrates that increase bioaffinity and decrease toxicity are in progress. For instance, sulfur from the QD shell is able to form reversible disulfide bonds with a wide class of organic compounds.
Sources: en.wikipedia.org
Duterte campaigned for decentralization and a shift to a federal government during the 2016 presidential election. In an October 2014 forum organized by Federal Movement for a Better Philippines in Cebu City prior to joining the presidential race, the then-mayor of Davao City called for the creation of two federal states for Moro people as a solution to the problems besetting Mindanao. Mayor Duterte said that Nur Misuari and his Moro National Liberation Front do not see eye-to-eye with the Moro Islamic Liberation Front which the administration of President Benigno Aquino III had inked a peace deal with. He also said that the "template of the Bangsamoro Basic Law is federal", but what is granted to the Bangsamoro should also be granted to other Moro groups and other regions in the country. In a dialogue with the Makati Business Club prior to the elections, Duterte said he is open to "toning down the Constitution" to accommodate more foreign investors to the Philippines. He also said he is open to up to 70 percent foreign ownership of businesses in the country and foreign lease of lands up to 60 years, but will "leave it to Congress to decide".
The methods and concepts presented in the Essai were further developed in later works, including Plantes équinoxiales which catalogued the thousands of plant specimens collected during his travels, many of them previously unknown to science. In the field of geology and climatology, Humboldt’s Recueil d’observations de zoologie et d’anatomie comparée and his monograph on the geology and climatology of South America offered comprehensive new perspectives. He was the first to produce geological cross-sections based on quantitative measurements, using barometric readings and the compass to map the structure and composition of mountain ranges and volcanic regions. His investigations of the Andes and Mexican volcanoes, including detailed studies of eruptions such as that of Jorullo, fostered a new understanding of vulcanism. Humboldt’s observations showed that volcanoes are often aligned along fissures in the earth’s crust, helping to shift geological thought away from Werner’s “neptunist” model toward a synthesis that recognized the role of internal heat and tectonic forces. His rigorous meteorological observations, employing thermometers, barometers, hygrometers, and magnetic instruments, produced the first reliable data on temperature, pressure, humidity, and magnetic phenomena across the Americas. Humboldt introduced the concept of isothermal lines—lines connecting points of equal mean temperature—making possible global comparisons of climate and advancing the study of climatology and physical geography.
== History == Many theories of the origin of the Weimaraner have been advanced, but there are few documented historical facts; silver-grey dogs are shown in paintings by Antoon van Dyck in the seventeenth century and by Jean-Baptiste Oudry in the eighteenth. The breed is believed to have originated in the area of the city of Weimar (then in Saxe-Weimar-Eisenach, now in the state of Thuringia) – the city from which its name derives. It is sometimes claimed that the dogs were kept at the court of Karl August, Grand Duke of Saxe-Weimar-Eisenach, in the early nineteenth century. From 1879 the dogs were considered to be a blue variant of the German Short-haired Pointer, and were eligible for registration in the stud-book of the Kurzhaar Klub. They first appeared at a dog show in 1880, when fourteen examples were presented in Berlin. These were of three differing types, from three different kennels: the traditional Thüringer Hund; the Weißenfelser Hund, which was rather more elegant; and the Sanderslebener, which was intermediate between the two. The Weimaraner was recognised as a distinct breed in 1891. A breed standard was drawn up in 1896, and in 1897 a breed association was established in Erfurt with the name Verein zur Reinzucht des silbergrauen Weimaraner-Vorstehhund; this was soon changed to Verein zur Züchtung des Weimaraner Vorstehhundes. In the early years of the twentieth century – the time of the Great War – the Weimaraner came close to extinction; it was reconstituted from the few surviving examples of the breed.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.